Skip to main content

Geovax Labs Inc WT(GOVXW-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Data Published in a Lancet Journal on COH04S1, a City of Hope-Developed COVID-19 Vaccine, Shows it Produced Robust Antibodies and T cells Against SARS-CoV-2

Globe Newswire - Thu Mar 10, 2022

The investigational vaccine is now being used in Phase 2 trials for immunocompromised patients and as a booster for healthy adult volunteers

LOS ANGELES and ATLANTA, March 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – A COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to GeoVax Labs Inc. (Nasdaq: GOVX), produced a robust neutralizing antibody and T cell (an immune cell) response against SARS-CoV-2 with no significant side effects in a Phase 1 clinical trial led by John Zaia, M.D., Aaron D. Miller and Edith Miller Chair for Gene Therapy, according to a study published today in The Lancet Microbe.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

opinion
Four reasons why wealthy investors should hold farmland in their portfolios
Andrea Gruza